Pauline Lempens

ORCID: 0000-0003-4526-6825
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Tuberculosis Research and Epidemiology
  • Mycobacterium research and diagnosis
  • RNA and protein synthesis mechanisms
  • Antibiotic Resistance in Bacteria
  • HIV/AIDS drug development and treatment
  • Pneumonia and Respiratory Infections
  • Pneumocystis jirovecii pneumonia detection and treatment

University of Antwerp
2020-2023

Instituut voor Tropische Geneeskunde
2018-2023

Tracking recent transmission is a vital part of controlling widespread pathogens such as Mycobacterium tuberculosis. Multiple methods with specific performance characteristics exist for detecting chains, usually by clustering strains based on genotype similarities. With large variety available, informed selection an appropriate approach determining transmissions within given setting/time period difficult.This study combines whole genome sequence (WGS) data derived from 324 isolates collected...

10.1016/j.ebiom.2018.10.013 article EN cc-by EBioMedicine 2018-10-16

Abstract The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG . Since these mutations cause wide range minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), drug might still remain partly active presence mutation. We therefore investigated which genetic predict phenotypic resistance clinical M. isolates. To this end, association between known and unknown...

10.1038/s41598-018-21378-x article EN cc-by Scientific Reports 2018-02-13

Abstract Heteroresistance - the simultaneous presence of drug-susceptible and -resistant organisms is common in Mycobacterium tuberculosis . In this study, we aimed to determine limit detection (LOD) genotypic assays detect gatifloxacin-resistant mutants experimentally mixed populations. A fluoroquinolone-susceptible M. mother strain (S) its vitro selected resistant daughter harbouring D94G mutation gyrA (R) were at different ratio’s. Minimum inhibitory concentrations (MICs) against...

10.1038/s41598-019-48289-9 article EN cc-by Scientific Reports 2019-08-13

ObjectivesWe investigated whether companion drug resistance was associated with adverse outcomes of the shorter multidrug-resistant tuberculosis (MDR-TB) treatment regimen in Bangladesh after adjustment for fluoroquinolone resistance.MethodsMDR-TB/rifampicin-resistant patients registered a standardized gatifloxacin-based MDR-TB were selected study. Drug determined by proportion method, gatifloxacin and isoniazid minimum inhibitory concentration testing isolates, whole-genome...

10.1016/j.ijid.2020.08.042 article EN cc-by-nc-nd International Journal of Infectious Diseases 2020-08-20

The spread of multidrug-resistant tuberculosis (MDR-TB) is a growing problem in many countries worldwide. Resistance to one the primary first-line drugs, rifampicin, caused by mutations Mycobacterium rpoB gene. So-called borderline confer low-level resistance, contrast more common which high-level resistance. While some show lower fitness vitro than mutations, their vivo currently unknown. We used dataset 394 whole genome sequenced MDR-TB isolates from Bangladesh, representing around 44 %...

10.1099/mgen.0.001109 article EN cc-by Microbial Genomics 2023-09-26

Mycobacterium tuberculosis rapid diagnostic tests (RDTs) are widely employed in routine laboratories and national surveys for detection of rifampicin-resistant (RR)-TB. However, as next-generation sequencing technologies have become more commonplace research surveillance programs, RDTs being increasingly complemented by whole genome (WGS). While comparison between is difficult, all RDT results can be derived from WGS data. This facilitate continuous analysis RR-TB burden regardless the data...

10.7717/peerj.7564 article EN cc-by PeerJ 2019-08-26

Abstract Background Tracking recent transmission is a vital part of controlling widespread pathogens such as Mycobacterium tuberculosis . Multiple methods with specific performance characteristics exist for detecting chains, usually by clustering strains based on genotype similarities. With large variety available, informed selection an appropriate approach determining transmissions within given setting/time period difficult. Methods This study combines whole genome sequence (WGS) data...

10.1101/302232 preprint EN cc-by-nd bioRxiv (Cold Spring Harbor Laboratory) 2018-04-16

Abstract The spread of multidrug-resistant tuberculosis (MDR-TB) is a growing problem in many countries worldwide. Resistance to one the primary first-line drugs, rifampicin, caused by mutations Mycobacterium rpoB gene. While some these infrequent show lower fitness vitro than more common mutations, their vivo currently unknown. We used dataset 394 whole genome sequenced MDR-TB isolates from Bangladesh, representing around 44% notified cases over 6 years, look at differences transmission...

10.1101/2023.02.14.528501 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2023-02-15

Abstract Background Mycobacterium tuberculosis rapid diagnostic tests (RDTs) are widely employed in routine laboratories and national surveys for detection of rifampicin-resistant (RR)-TB. However, as next generation sequencing technologies have become more commonplace research surveillance programs, RDTs being increasingly complemented by whole genome (WGS). While comparison between is difficult, all RDT results can be derived from WGS data. This facilitate continuous analysis RR-TB burden...

10.1101/628099 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2019-05-05

Background: Rifampicin-resistance (RR) poses an important challenge in tuberculosis (TB) management and control. Understanding the driving factors behind rising numbers of RR-TB is for developing appropriate control strategies.Methods: We analysed whole genome sequences a longitudinal nationwide collection (308 isolates): before programmatic (PMDT; 1991-2005), early PMDT phase (2006-2013; rifampicin testing retreatment patients only), consolidated (2014-2018; all patients). reconstructed...

10.2139/ssrn.3792898 article EN SSRN Electronic Journal 2021-01-01
Coming Soon ...